Development of Fecal Microbiota Transplantation Suitable for Mainstream Medicine
Development of Fecal Microbiota Transplantation Suitable for Mainstream Medicine
复制标题
DOI：
10.1016/j.cgh.2014.11.014
复制
发表时间：
2015-02-01
影响因子：
12.6
通讯作者：
Hamilton, Matthew J.
中科院分区：
文献类型：
--
作者：
Khoruts, Alexander;Sadowsky, Michael J.;Hamilton, Matthew J.
粪便微生物群移植已成为难治性艰难梭菌感染患者越来越常见的治疗方法。虽然它可以相对简单的执行，一些挑战需要克服之前，这一程序被广泛接受的主流临床实践。这些挑战的大多数解决方案已经存在，但有些需要进一步优化和测试。标准化的粪便微生物群正在被开发为治疗剂，尽管它显然挑战了一些现有的药物开发、递送和监管范式。
Fecal microbiota transplantation has emerged as an increasingly common treatment for patients with refractory Clostridium difficile infection. Although it can be relatively simple to perform, a number of challenges need to be overcome before this procedure is widely accepted in mainstream clinical practice. Most of the solutions to these challenges already exist, but some need further optimization and testing. Standardized fecal microbiota is being developed as a therapeutic agent, although it clearly challenges some of the existing paradigms of drug development, delivery, and regulation.